Furthermore, the lack of significant alterations in striatal DAT availability in previous meta-analyses (Brugger et al., 2020; Howes et al., 2012) could be attributed to the high variability in DAT availability reported in schizophrenia (Brugger et al., 2020), with reductions potentially limited to a subgroup of patients with significant cognitive impairment (Lewandowski et al., 2019). The gene discussed is SLC6A3; the disease is Cognitive impairment.